Shanta Zimmer
Concepts (293)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza, Human | 13 | 2021 | 640 | 1.080 |
Why?
| | Influenza A Virus, H1N1 Subtype | 8 | 2011 | 162 | 0.910 |
Why?
| | Physician-Patient Relations | 3 | 2016 | 597 | 0.650 |
Why?
| | Physicians, Women | 1 | 2020 | 92 | 0.580 |
Why?
| | Coronavirus Infections | 2 | 2023 | 379 | 0.560 |
Why?
| | Vulnerable Populations | 1 | 2020 | 178 | 0.560 |
Why?
| | Neisseria meningitidis | 3 | 2007 | 23 | 0.550 |
Why?
| | Lymphocyte Antigen 96 | 3 | 2008 | 23 | 0.540 |
Why?
| | Communicable Diseases | 1 | 2020 | 166 | 0.540 |
Why?
| | Internship and Residency | 6 | 2019 | 1281 | 0.480 |
Why?
| | Professional Misconduct | 1 | 2016 | 13 | 0.460 |
Why?
| | Meningitis, Meningococcal | 2 | 2006 | 6 | 0.450 |
Why?
| | Pennsylvania | 8 | 2021 | 136 | 0.450 |
Why?
| | Faculty | 1 | 2016 | 152 | 0.430 |
Why?
| | Meningococcal Vaccines | 2 | 2006 | 57 | 0.430 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 387 | 0.430 |
Why?
| | Curriculum | 4 | 2024 | 1079 | 0.410 |
Why?
| | Internal Medicine | 4 | 2018 | 280 | 0.390 |
Why?
| | Seroepidemiologic Studies | 2 | 2021 | 171 | 0.350 |
Why?
| | Influenza Vaccines | 6 | 2011 | 544 | 0.340 |
Why?
| | Physicians | 3 | 2016 | 955 | 0.320 |
Why?
| | Computer Simulation | 9 | 2012 | 1014 | 0.300 |
Why?
| | Toll-Like Receptor 4 | 4 | 2008 | 277 | 0.300 |
Why?
| | Reassortant Viruses | 1 | 2009 | 8 | 0.300 |
Why?
| | Education, Medical, Undergraduate | 1 | 2012 | 208 | 0.300 |
Why?
| | Education, Medical, Graduate | 4 | 2019 | 568 | 0.300 |
Why?
| | Students, Medical | 2 | 2024 | 383 | 0.290 |
Why?
| | Communicable Diseases, Emerging | 1 | 2009 | 39 | 0.290 |
Why?
| | Zoonoses | 1 | 2009 | 39 | 0.290 |
Why?
| | Lipid A | 3 | 2007 | 27 | 0.280 |
Why?
| | Orthomyxoviridae Infections | 1 | 2009 | 72 | 0.280 |
Why?
| | Respiratory Tract Infections | 2 | 2023 | 403 | 0.260 |
Why?
| | Zygomycosis | 1 | 2007 | 6 | 0.250 |
Why?
| | Cyclosporiasis | 1 | 2007 | 1 | 0.250 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2008 | 178 | 0.250 |
Why?
| | Dermatomycoses | 1 | 2007 | 8 | 0.250 |
Why?
| | Paclitaxel | 1 | 2008 | 260 | 0.250 |
Why?
| | Oxazolidinones | 2 | 2004 | 16 | 0.250 |
Why?
| | Acetamides | 2 | 2004 | 42 | 0.240 |
Why?
| | Gram-Positive Bacterial Infections | 2 | 2005 | 72 | 0.240 |
Why?
| | Thiazoles | 1 | 2007 | 139 | 0.240 |
Why?
| | Sexual and Gender Minorities | 2 | 2022 | 269 | 0.230 |
Why?
| | Fungi | 1 | 2007 | 120 | 0.230 |
Why?
| | Drug Hypersensitivity | 1 | 2007 | 93 | 0.220 |
Why?
| | Triazoles | 1 | 2007 | 190 | 0.220 |
Why?
| | Humans | 50 | 2024 | 146342 | 0.220 |
Why?
| | Schools | 4 | 2021 | 436 | 0.220 |
Why?
| | Leadership | 2 | 2020 | 414 | 0.220 |
Why?
| | History, 21st Century | 2 | 2020 | 224 | 0.220 |
Why?
| | Disease Outbreaks | 5 | 2010 | 422 | 0.210 |
Why?
| | History, 20th Century | 2 | 2020 | 330 | 0.210 |
Why?
| | Exploratory Behavior | 1 | 2024 | 86 | 0.200 |
Why?
| | Medical Tourism | 1 | 2023 | 9 | 0.200 |
Why?
| | Coronavirus NL63, Human | 1 | 2023 | 3 | 0.190 |
Why?
| | Coronavirus OC43, Human | 1 | 2023 | 7 | 0.190 |
Why?
| | Coronavirus 229E, Human | 1 | 2023 | 7 | 0.190 |
Why?
| | Enterococcus faecalis | 1 | 2003 | 29 | 0.190 |
Why?
| | Models, Molecular | 1 | 2008 | 1574 | 0.190 |
Why?
| | Endocarditis, Bacterial | 1 | 2003 | 46 | 0.190 |
Why?
| | Sulfonamides | 1 | 2007 | 594 | 0.190 |
Why?
| | Clinical Clerkship | 1 | 2024 | 111 | 0.180 |
Why?
| | Meningitis | 1 | 2023 | 80 | 0.180 |
Why?
| | Models, Economic | 3 | 2012 | 63 | 0.180 |
Why?
| | Mycobacterium abscessus | 1 | 2023 | 110 | 0.170 |
Why?
| | Pre-Exposure Prophylaxis | 2 | 2022 | 272 | 0.160 |
Why?
| | Viruses | 1 | 2023 | 165 | 0.160 |
Why?
| | Emergency Responders | 1 | 2021 | 38 | 0.160 |
Why?
| | Program Evaluation | 3 | 2019 | 952 | 0.160 |
Why?
| | Crowding | 1 | 2020 | 37 | 0.150 |
Why?
| | Awards and Prizes | 1 | 2020 | 72 | 0.150 |
Why?
| | Shoulder | 1 | 2020 | 105 | 0.150 |
Why?
| | Frail Elderly | 1 | 2020 | 141 | 0.140 |
Why?
| | Prisons | 1 | 2020 | 88 | 0.140 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2023 | 339 | 0.140 |
Why?
| | Evidence-Based Medicine | 2 | 2024 | 731 | 0.140 |
Why?
| | Surgery Department, Hospital | 1 | 2018 | 23 | 0.140 |
Why?
| | Virus Diseases | 1 | 2021 | 219 | 0.140 |
Why?
| | Minority Groups | 1 | 2020 | 286 | 0.140 |
Why?
| | Financing, Organized | 1 | 2018 | 36 | 0.140 |
Why?
| | Nursing Homes | 1 | 2020 | 171 | 0.140 |
Why?
| | Faculty, Medical | 2 | 2018 | 309 | 0.130 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2018 | 147 | 0.130 |
Why?
| | Adult | 18 | 2023 | 41087 | 0.130 |
Why?
| | Point-of-Care Systems | 2 | 2017 | 185 | 0.130 |
Why?
| | Preceptorship | 1 | 2017 | 68 | 0.130 |
Why?
| | Betacoronavirus | 1 | 2020 | 288 | 0.120 |
Why?
| | Urban Population | 1 | 2020 | 497 | 0.120 |
Why?
| | Clinical Competence | 3 | 2024 | 1272 | 0.120 |
Why?
| | Population Surveillance | 2 | 2011 | 481 | 0.120 |
Why?
| | Occupational Exposure | 1 | 2020 | 356 | 0.120 |
Why?
| | Societies, Medical | 1 | 2020 | 907 | 0.120 |
Why?
| | Anesthesiology | 1 | 2018 | 178 | 0.110 |
Why?
| | Endotoxins | 2 | 2007 | 215 | 0.110 |
Why?
| | Fellowships and Scholarships | 1 | 2019 | 355 | 0.110 |
Why?
| | Continuity of Patient Care | 1 | 2017 | 298 | 0.110 |
Why?
| | Rural Population | 1 | 2020 | 677 | 0.110 |
Why?
| | Sexual Behavior | 1 | 2019 | 490 | 0.110 |
Why?
| | HIV Infections | 2 | 2022 | 3215 | 0.110 |
Why?
| | Female | 18 | 2022 | 79499 | 0.110 |
Why?
| | Binding Sites | 2 | 2008 | 1309 | 0.100 |
Why?
| | Recombinant Proteins | 2 | 2008 | 1361 | 0.100 |
Why?
| | Antiviral Agents | 2 | 2011 | 779 | 0.100 |
Why?
| | Cardiology | 1 | 2017 | 363 | 0.100 |
Why?
| | Anti-HIV Agents | 1 | 2022 | 914 | 0.100 |
Why?
| | United States | 7 | 2020 | 16136 | 0.100 |
Why?
| | Hand Hygiene | 1 | 2013 | 9 | 0.100 |
Why?
| | Work Schedule Tolerance | 1 | 2013 | 51 | 0.100 |
Why?
| | Macrophage Activation | 2 | 2005 | 182 | 0.100 |
Why?
| | Male | 17 | 2022 | 73396 | 0.090 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2013 | 102 | 0.090 |
Why?
| | Anti-Bacterial Agents | 1 | 2003 | 1942 | 0.090 |
Why?
| | Macrophages | 4 | 2008 | 1532 | 0.090 |
Why?
| | Receptors, Cell Surface | 2 | 2005 | 371 | 0.090 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2011 | 2240 | 0.090 |
Why?
| | Membrane Glycoproteins | 2 | 2005 | 495 | 0.090 |
Why?
| | Patients | 1 | 2013 | 183 | 0.090 |
Why?
| | Patient Admission | 1 | 2013 | 216 | 0.090 |
Why?
| | Social Support | 1 | 2016 | 646 | 0.090 |
Why?
| | Surveys and Questionnaires | 3 | 2021 | 6073 | 0.080 |
Why?
| | Pandemics | 1 | 2020 | 1707 | 0.080 |
Why?
| | Antibodies, Viral | 2 | 2021 | 689 | 0.080 |
Why?
| | Poverty Areas | 1 | 2011 | 43 | 0.080 |
Why?
| | Guanidines | 1 | 2011 | 39 | 0.080 |
Why?
| | Cyclopentanes | 1 | 2011 | 17 | 0.080 |
Why?
| | Genetic Predisposition to Disease | 2 | 2011 | 2488 | 0.080 |
Why?
| | Health Care Costs | 2 | 2011 | 423 | 0.080 |
Why?
| | Patient Preference | 1 | 2013 | 226 | 0.080 |
Why?
| | Hemagglutinins | 1 | 2010 | 10 | 0.080 |
Why?
| | Pneumococcal Infections | 1 | 2011 | 104 | 0.080 |
Why?
| | Aged | 8 | 2020 | 26432 | 0.080 |
Why?
| | Clostridium Infections | 1 | 2011 | 75 | 0.080 |
Why?
| | Students | 1 | 2016 | 649 | 0.080 |
Why?
| | Hospitalization | 1 | 2020 | 2475 | 0.080 |
Why?
| | Quarantine | 1 | 2010 | 31 | 0.080 |
Why?
| | Quality Improvement | 1 | 2019 | 1354 | 0.080 |
Why?
| | Health Care Rationing | 1 | 2010 | 54 | 0.080 |
Why?
| | Occupational Health Services | 1 | 2009 | 36 | 0.080 |
Why?
| | Staphylococcal Infections | 2 | 2012 | 397 | 0.080 |
Why?
| | Influenza A Virus, H2N2 Subtype | 1 | 2009 | 1 | 0.070 |
Why?
| | Seasons | 2 | 2023 | 540 | 0.070 |
Why?
| | Communication | 1 | 2016 | 980 | 0.070 |
Why?
| | Antigenic Variation | 1 | 2009 | 12 | 0.070 |
Why?
| | Adjuvants, Immunologic | 1 | 2011 | 245 | 0.070 |
Why?
| | Antibody Specificity | 1 | 2009 | 181 | 0.070 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2012 | 253 | 0.070 |
Why?
| | Asthma | 1 | 2020 | 1800 | 0.070 |
Why?
| | Birds | 1 | 2009 | 87 | 0.070 |
Why?
| | Young Adult | 7 | 2020 | 14330 | 0.070 |
Why?
| | Cross Infection | 1 | 2011 | 258 | 0.070 |
Why?
| | Child | 9 | 2023 | 22693 | 0.070 |
Why?
| | Primary Prevention | 1 | 2010 | 222 | 0.070 |
Why?
| | Disease Management | 1 | 2012 | 651 | 0.070 |
Why?
| | Meningitis, Bacterial | 1 | 2008 | 52 | 0.070 |
Why?
| | Carbohydrate Conformation | 1 | 2007 | 16 | 0.060 |
Why?
| | Genome, Viral | 1 | 2009 | 217 | 0.060 |
Why?
| | Pichia | 1 | 2007 | 20 | 0.060 |
Why?
| | Protein Structure, Secondary | 1 | 2008 | 357 | 0.060 |
Why?
| | Cell Line | 3 | 2008 | 2814 | 0.060 |
Why?
| | Cyclospora | 1 | 2007 | 1 | 0.060 |
Why?
| | Antiparasitic Agents | 1 | 2007 | 4 | 0.060 |
Why?
| | Surface Properties | 1 | 2008 | 384 | 0.060 |
Why?
| | Tubulin | 1 | 2008 | 124 | 0.060 |
Why?
| | Child, Preschool | 7 | 2021 | 11913 | 0.060 |
Why?
| | Nitro Compounds | 1 | 2007 | 8 | 0.060 |
Why?
| | Species Specificity | 1 | 2008 | 543 | 0.060 |
Why?
| | Linezolid | 2 | 2004 | 25 | 0.060 |
Why?
| | Renal Dialysis | 1 | 2011 | 461 | 0.060 |
Why?
| | District of Columbia | 3 | 2011 | 37 | 0.060 |
Why?
| | Swine | 1 | 2009 | 821 | 0.060 |
Why?
| | Neonatal Screening | 1 | 2008 | 185 | 0.060 |
Why?
| | Phylogeny | 1 | 2010 | 924 | 0.060 |
Why?
| | Chronic Disease | 1 | 2012 | 1827 | 0.060 |
Why?
| | Antifungal Agents | 1 | 2007 | 153 | 0.060 |
Why?
| | Protein Structure, Tertiary | 1 | 2008 | 834 | 0.060 |
Why?
| | Vancomycin Resistance | 1 | 2005 | 16 | 0.060 |
Why?
| | Enterococcus | 1 | 2005 | 22 | 0.060 |
Why?
| | Evolution, Molecular | 1 | 2009 | 502 | 0.060 |
Why?
| | Antigens, Differentiation | 1 | 2005 | 75 | 0.050 |
Why?
| | Adolescent | 7 | 2022 | 22557 | 0.050 |
Why?
| | Transfection | 1 | 2007 | 916 | 0.050 |
Why?
| | Efficiency | 2 | 2019 | 102 | 0.050 |
Why?
| | Vaccines, Conjugate | 1 | 2004 | 60 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2008 | 2022 | 0.050 |
Why?
| | Receptors, Immunologic | 1 | 2005 | 210 | 0.050 |
Why?
| | Lipopolysaccharides | 2 | 2005 | 861 | 0.050 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2008 | 1224 | 0.050 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2004 | 88 | 0.050 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2004 | 135 | 0.050 |
Why?
| | Animals | 5 | 2009 | 38107 | 0.050 |
Why?
| | Middle Aged | 9 | 2021 | 36619 | 0.050 |
Why?
| | Molecular Sequence Data | 1 | 2007 | 2838 | 0.050 |
Why?
| | Bacteremia | 1 | 2005 | 218 | 0.050 |
Why?
| | Health Services Accessibility | 1 | 2011 | 1107 | 0.050 |
Why?
| | Odds Ratio | 2 | 2021 | 1077 | 0.050 |
Why?
| | Models, Statistical | 3 | 2011 | 669 | 0.040 |
Why?
| | Aged, 80 and over | 4 | 2020 | 8391 | 0.040 |
Why?
| | Protein Binding | 1 | 2008 | 2244 | 0.040 |
Why?
| | Anti-Infective Agents | 1 | 2004 | 234 | 0.040 |
Why?
| | Influenza B virus | 1 | 2021 | 47 | 0.040 |
Why?
| | Contact Tracing | 1 | 2021 | 26 | 0.040 |
Why?
| | Infant | 4 | 2012 | 10114 | 0.040 |
Why?
| | Monte Carlo Method | 2 | 2011 | 151 | 0.040 |
Why?
| | Absenteeism | 1 | 2021 | 51 | 0.040 |
Why?
| | Membrane Cofactor Protein | 2 | 2011 | 14 | 0.040 |
Why?
| | Homosexuality, Male | 1 | 2022 | 231 | 0.040 |
Why?
| | Ecology | 1 | 2021 | 106 | 0.040 |
Why?
| | Learning | 1 | 2024 | 446 | 0.040 |
Why?
| | Risk Factors | 3 | 2021 | 10921 | 0.040 |
Why?
| | Cells, Cultured | 1 | 2007 | 4118 | 0.040 |
Why?
| | Stem Cells | 1 | 2023 | 613 | 0.040 |
Why?
| | Regression Analysis | 1 | 2021 | 999 | 0.030 |
Why?
| | Temperature | 1 | 2021 | 635 | 0.030 |
Why?
| | Cost-Benefit Analysis | 2 | 2011 | 640 | 0.030 |
Why?
| | Diabetes Mellitus | 1 | 2007 | 1101 | 0.030 |
Why?
| | Schools, Medical | 1 | 2019 | 158 | 0.030 |
Why?
| | Intubation, Intratracheal | 1 | 2020 | 330 | 0.030 |
Why?
| | Polymerase Chain Reaction | 2 | 2011 | 1031 | 0.030 |
Why?
| | Medication Adherence | 1 | 2022 | 535 | 0.030 |
Why?
| | Feedback | 1 | 2018 | 183 | 0.030 |
Why?
| | Models, Educational | 1 | 2017 | 91 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2021 | 901 | 0.030 |
Why?
| | Diagnostic Errors | 1 | 2018 | 178 | 0.030 |
Why?
| | Cohort Studies | 2 | 2021 | 6077 | 0.030 |
Why?
| | Respiration, Artificial | 1 | 2020 | 711 | 0.030 |
Why?
| | Mice | 3 | 2008 | 18297 | 0.030 |
Why?
| | Logistic Models | 1 | 2020 | 2126 | 0.030 |
Why?
| | Focus Groups | 1 | 2018 | 588 | 0.030 |
Why?
| | Educational Measurement | 1 | 2018 | 331 | 0.030 |
Why?
| | Infant, Newborn | 3 | 2012 | 6460 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2020 | 925 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 365 | 0.030 |
Why?
| | Age Factors | 1 | 2021 | 3347 | 0.020 |
Why?
| | Toll-Like Receptors | 2 | 2005 | 193 | 0.020 |
Why?
| | Biomedical Research | 1 | 2019 | 729 | 0.020 |
Why?
| | Sex Factors | 1 | 2018 | 2107 | 0.020 |
Why?
| | Body Mass Index | 1 | 2020 | 2458 | 0.020 |
Why?
| | Pulmonary Surfactant-Associated Protein D | 1 | 2011 | 31 | 0.020 |
Why?
| | Receptors, Interleukin-1 Type I | 1 | 2011 | 25 | 0.020 |
Why?
| | Signal Transduction | 1 | 2005 | 5246 | 0.020 |
Why?
| | Acids, Carbocyclic | 1 | 2011 | 1 | 0.020 |
Why?
| | Decision Trees | 1 | 2011 | 76 | 0.020 |
Why?
| | Referral and Consultation | 1 | 2017 | 881 | 0.020 |
Why?
| | Stochastic Processes | 1 | 2011 | 65 | 0.020 |
Why?
| | Data Collection | 1 | 2013 | 650 | 0.020 |
Why?
| | Colorado | 1 | 2021 | 4595 | 0.020 |
Why?
| | Quality-Adjusted Life Years | 1 | 2011 | 122 | 0.020 |
Why?
| | Attitude to Health | 1 | 2013 | 421 | 0.020 |
Why?
| | Diarrhea | 1 | 2011 | 190 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2011 | 329 | 0.020 |
Why?
| | Community-Acquired Infections | 1 | 2012 | 179 | 0.020 |
Why?
| | Gene Frequency | 1 | 2011 | 496 | 0.020 |
Why?
| | Mass Vaccination | 1 | 2009 | 18 | 0.020 |
Why?
| | Calibration | 1 | 2010 | 154 | 0.020 |
Why?
| | Cost of Illness | 1 | 2012 | 323 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2011 | 432 | 0.020 |
Why?
| | Immunization Programs | 1 | 2011 | 194 | 0.020 |
Why?
| | Streptococcus pneumoniae | 1 | 2011 | 187 | 0.020 |
Why?
| | Travel | 1 | 2010 | 134 | 0.020 |
Why?
| | Efficiency, Organizational | 1 | 2010 | 144 | 0.020 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1408 | 0.020 |
Why?
| | Host-Pathogen Interactions | 1 | 2011 | 366 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2022 | 17438 | 0.020 |
Why?
| | Workplace | 1 | 2009 | 268 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2010 | 385 | 0.020 |
Why?
| | Occupational Health | 1 | 2009 | 212 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2011 | 1327 | 0.020 |
Why?
| | Genotype | 1 | 2011 | 1879 | 0.010 |
Why?
| | Decision Support Techniques | 1 | 2011 | 478 | 0.010 |
Why?
| | Pilot Projects | 1 | 2011 | 1888 | 0.010 |
Why?
| | Environmental Exposure | 1 | 2010 | 578 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 2005 | 252 | 0.010 |
Why?
| | Kidney Failure, Chronic | 1 | 2011 | 589 | 0.010 |
Why?
| | Gram-Negative Bacteria | 1 | 2005 | 80 | 0.010 |
Why?
| | DNA | 1 | 2011 | 1421 | 0.010 |
Why?
| | Growth | 1 | 2004 | 48 | 0.010 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2005 | 119 | 0.010 |
Why?
| | Incidence | 1 | 2011 | 2936 | 0.010 |
Why?
| | Sugar Acids | 1 | 2004 | 4 | 0.010 |
Why?
| | Respiratory Burst | 1 | 2004 | 19 | 0.010 |
Why?
| | U937 Cells | 1 | 2004 | 28 | 0.010 |
Why?
| | Feasibility Studies | 1 | 2008 | 1135 | 0.010 |
Why?
| | Antigens, Surface | 1 | 2004 | 155 | 0.010 |
Why?
| | Models, Biological | 1 | 2010 | 1761 | 0.010 |
Why?
| | Toll-Like Receptor 2 | 1 | 2004 | 125 | 0.010 |
Why?
| | Vaccination | 1 | 2011 | 1449 | 0.010 |
Why?
| | Structure-Activity Relationship | 1 | 2004 | 563 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2017 | 11821 | 0.010 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2005 | 429 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2013 | 5899 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2008 | 3647 | 0.010 |
Why?
| | Nitric Oxide | 1 | 2005 | 883 | 0.010 |
Why?
| | Time Factors | 1 | 2009 | 7109 | 0.010 |
Why?
| | Cytokines | 1 | 2005 | 2081 | 0.010 |
Why?
|
|
Zimmer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|